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Abstract. Bevacizumab (BV) is a humanized monoclonal anti-
body that inhibits angiogenesis by targeting vascular endothelial 
growth factor (VEGF). The addition of BV to combination 
chemotherapy has been shown to improve the outcomes in several 
malignancies, including colorectal carcinoma (CRC). However, 
the use of BV has been associated with adverse effects, including 
hypertension, hemorrhage, proteinuria, delayed wound healing 
and bowel perforation. Pneumothorax (PTX) as an adverse event 
associated with BV use has rarely been reported. We herein 
report the case of a 68-year-old female patient with a history 
of metastatic CRC treated with combination chemotherapy, 
including BV, who presented with complaints of shortness of 
breath and was found to have a right-sided PTX.
Introduction
The vascular endothelial growth factor (VEGF)/VEGF- 
receptor pathway plays a key role in malignant tumor 
angiogenesis (1). This has led to the development of humanized 
monoclonal antibodies targeted against this pathway to inhibit 
tumor angiogenesis. Bevacizumab (BV) was the first approved 
anti-VEGF antibody (2) and it has become a standard part of 
several combination chemotherapy regimens used in patients 
with metastatic colorectal cancer (mCRC), after having been 
shown by several clinical trial to exert a statistically significant 
favorable effect on overall survival (OS) and progression-free 
survival (PFS) (3). Some of the most common adverse 
events associated with the use of BV include hypertension, 
hemorrhage, proteinuria, delayed wound healing and bowel 
perforation (4). Some have reported increased risk of arterial 
events, mainly cardiovascular and cerebrovascular events (5). 
However, pneumothorax (PTX) has rarely been reported in 
association with the use of BV (6-12). We herein report the 
case of a 68-year-old female patient who was undergoing 
third‑line chemotherapy with folinic acid, fluorouracil (5‑FU) 
and oxaliplatin (FOLFOX) plus BV when she presented with 
shortness of breath (SOB) and was diagnosed with pneumohy-
drothorax. We consider the present case to be important, as it 
sheds light on a rare adverse event associated with the use of 
BV, in an era where VEGF-inhibitors are being implemented 
in the treatment of several malignancies. Clinicians should be 
aware of this potential adverse event in order to possess a high 
clinical index of suspicion for making this diagnosis.
Case report
A 68-year-old female patient presented in January 2018 to 
Saint Joseph's Hospital (Chicago, USA) with complaints of 
worsening SOB for 1 month, with an associated right-sided 
pleuritic chest pain and a dry cough. On physical examination, 
the patient was found to be mildly tachycardic to 102 beats 
per min, she was not tachypneic and her oxygen saturation was 
98% breathing ambient air. Physical examination was notable 
for decreased breath sounds over the right lower lung fields. 
Otherwise, the physical examination was unremarkable. This 
presentation was 1 week after the completion of the 4th cycle of 
combination chemotherapy with FOLFOX and BV for mCRC.
The patient was initially diagnosed with stage IIIB mCRC 
9 years earlier, for which she had undergone sigmoidectomy 
and completed 12 cycles of adjuvant chemotherapy with 
FOLFOX. Four years later, a positron emission tomography 
with computed tomography (PET/CT) scan revealed disease 
recurrence, with 3 metastatic lung lesions. The patient subse-
quently underwent Cyberknife therapy followed by 12 cycles of 
leucovorin, 5-FU and irinotecan (FOLFIRI) with cetuximab, 
followed by maintenance therapy with cetuximab. Two years 
later, a CT scan of the abdomen revealed evidence of a new 
left adrenal mass, which was treated with radiofrequency abla-
tion; a biopsy was consistent with metastatic adenocarcinoma. 
The patient was then placed on combination chemotherapy 
with FOLFIRI and BV followed by maintenance capecitabine, 
which she tolerated well, and a PET/CT scan 1 year later showed 
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no evidence of disease. However, 3 months later, an elevation 
in her carcinoembryonic antigen (CEA) levels was observed, 
and a PET/CT scan (Fig. 1) revealed disease recurrence with 
lesions in the right lung base, subcarinal mediastinal lymph 
node and a left adrenal mass. The patient was then started on 
combination chemotherapy with FOLFIRI and the endothe-
lial growth factor receptor inhibitor panitumumab. Disease 
progression was identified on restaging CT scan, along with 
an increase of the CEA levels; hence, the decision was made to 
start the patient on FOLFOX and BV. The patient had a family 
history of prostate cancer in her father and heart failure in her 
mother. The patient was a never smoker, and she did not drink 
alcohol or use illicit drugs.
The patient underwent a chest X-ray (Fig. 2), which revealed 
evidence of a moderate hydropneumothorax encompassing 
40% of the right hemithorax volume. There was also a stable 
opacity within the right perihilar region, which correlated with 
known metastatic disease.
The patient's PTX was considered to be secondary to the 
presence of an underlying pulmonary metastatic lesion in 
the setting of BV use. The patient was a never smoker, with 
no underlying obstructive lung disease; she had no chronic 
pulmonary conditions other than her metastatic disease that 
had been present for several years; she had also not had any 
recent chest trauma, or undergone any recent procedures.
The patient underwent ultrasound-guided placement of a 
10 French chest tube with evacuation of 200 ml of air. The 
chest tube was kept on water seal for 5 days, then clamped 
the next day, and a repeat X-ray revealed resolution of the 
PTX (Fig. 3). The chest tube was removed, and the patient 
was discharged.
BV was indefinitely discontinued and substituted with 
cetuximab. After the 7th cycle of chemotherapy, a restaging 
PET/CT scan revealed enlargement of the right basilar 
lung mass with new right hilar and mediastinal lymphade-
nopathy, indicating progression of disease (POD). The patient 
completed 12 cycles of the current chemotherapy regimen, 
and POD occurred again, after which time she was started 
on trifluridine and tipiracil. The patient was then admitted to 
the hospital with acute encephalopathy and was found to have 
sepsis secondary to pneumonia. A CT scan of the head revealed 
a 0.9-cm metastatic lesion in the left frontal lobe. Palliative 
and hospice care were recommended with services initiated 
during the same hospitalization. The patient succumbed to the 
disease 1 week after admission.
Discussion
BV is a recombinant humanized monoclonal antibody that 
exerts antitumor effects by binding to VEGF and inhibiting 
tumor angiogenesis (1). BV has been widely used in the treat-
ment of solid tumors, including CRC, renal cell carcinoma, 
ovarian carcinoma and several others (4). BV has several 
side effects pertaining to its antiangiogenic effects. However, 
PTX as a complication of BV use has rarely been reported. 
MEDLINE was searched using two keywords, namely ‘BV’ 
and ‘pneumothorax’; the search yielded a total of 15 results, 
7 of which were case reports relevant to the topic, and 
6 of which had text available in English (Table I).
In 5 of the reviewed cases, including the present case, 
pulmonary metastases were present. However, Zhang et al 
reported a case of PTX following treatment of fibrosarcoma 
where no lung lesions were present. Hence, PTX may occur 
even in the absence of metastatic disease. Patients with mCRC 
were more likely to develop PTX with BV (n=3), as compared 
with fibrosarcoma (n=1), synovial sarcoma (n=1) and breast 
cancer (n=1). It remains unclear whether this observation is a 
Figure 1. Positron emission tomography-computed tomography scan showing 
increased metabolic activity within a right lower lobe lung mass.
Figure 3. Repeat chest X-ray showing resolution of previously noted pneumo-
thorax with chest tube placement.
Figure 2. Right-sided pneumothorax with pleural effusion, encompassing 
~40% of the right hemithorax (arrows indicate the visceral pleura line).
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matter of chance, considering that mCRC is the second most 
common malignancy to metastasize to the lung (13), and the 
fact that mCRC is one of the most common indications for BV 
treatment. PTX in association with BV was observed following 
a variable number of therapy cycles.
Srinivas and Varadhachary proposed that malig-
nancy-associated PTX may result from tumor compression 
of the bronchial wall, leading to the formation of a one-way 
valve, resulting in air trapping and eventual rupture. Another 
potential cause is bronchopleural fistula formation as a result 
of effective chemotherapy, and spontaneous vascular occlusion 
within the tumor itself (14). Hence, it is possible that the anti-
angiogenic effect of BV, which leads to distortion of the tumor 
vasculature, may lead to PTX in peripherally located tumors. 
In addition to the suggested tumor-related mechanisms of 
PTX development, a study by Kasahara et al in animal models 
found that chronic treatment with VEGF inhibitors led to the 
distortion of the alveolar structure through the induction of 
cell apoptosis, suggesting that this may contribute to the devel-
opment of emphysema (15), which is a risk factor for PTX.
Our patient had also undergone radiosurgery with Cyberknife 
4 years prior to her current presentation. PTX has been reported 
with Cyberknife therapy following CT‑guided fiducial place-
ment (16), an acute complication that was not observed in our 
patient. CT scan of the chest following Cyberknife therapy did 
not show evidence of lung damage that would be attributable to 
that therapy. However, it is possible that our patient developed 
lung parenchymal damage secondary to radiation that was 
undetectable on imaging modalities and may have contributed 
to the development of PTX. However, we consider the PTX that 
she developed to be associated with her most recent treatment 
with BV in the setting of lung metastatic disease, as the PTX 
developed after the 4th dose of BV, and the fact that this patient 
had also received several cycles of chemotherapy following 
Cyberknife therapy (12 cycles of FOLFIRI and cetuximab, 
and 24 cycles of FOLFIRI and panitumumab), which were 
well-tolerated. Our patient had received BV in the past, which 
she also tolerated well; however, it is worth noting that, at the 
time, the patient did not display evidence of lung metastatic 
disease on imaging. Therefore, underlying lung parenchymal 
disease, including lung metastatic disease, may place patients at 
an increased risk of developing BV-associated PTX.
In a recent study of breast cancer patients published by 
Lodola et al, a finding suggested that the intracellular Ca2+ 
toolkit, which is responsible for the pro-angiogenic effect of 
VEGF, is remodeled in cancer patients and rendered insensi-
tive to VEGF (17). This suggests that these tumor cells are 
resistant to the angiogenic effect of VEGF, and may conse-
quently be resistant to VEGF inhibitors as anti-angiogenic 
agents. This finding suggests that VEGF inhibitors (including 
BV), may not have as important a role in tumor vascularization 
as previously thought, and raises the possibility that PTX, in 
addition to the other adverse effects of these agents, may be 
a result of an off-target effect rather than an anti-angiogenic 
effect. Further in vitro studies that investigate this off-target 
effect are required. These studies may also uncover, as the 
abovementioned study, potential novel targets, such as the 
store-operated Ca2+ entry mechanism.
It is difficult to ascertain the exact frequency of 
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the inability to ascertain the number of patients receiving 
BV therapy annually. However, Interiano et al conducted 
a retrospective analysis of selected pediatric patients with 
recurrent or refractory solid malignancies who had undergone 
combination therapy with BV and sorafenib with low-dose 
cyclophosphamide therapy. The goal of the analysis was 
to assess the risk of developing PTX. The study reported 
an unexpectedly high incidence of PTX in 11 of the 44 
subjects (25%) (18). Although that study was conducted in 
pediatric patients, its results are significant and suggest that 
BV-associated PTX may be occurring at higher rates than 
reported as compared to healthy individuals. In comparison, 
primary spontaneous PTX (PSP) in healthy individuals is esti-
mated to occur at a rate of 7.4-18 cases per 100,000 amongst 
males, and 6 cases per 100,000 amongst females. In addition, 
PSP rarely occurs after the age of 40 years (19).
It is possible that the lack of a significant number of case 
reports describing PTX in association with BV therapy is due 
to the lack of widespread knowledge of this association; hence, 
there may be a number of unreported such cases. Therefore, it 
is important to report these cases to spread awareness amongst 
clinicians to this potentially life-threatening collateral effect 
of BV. There is also the need for further studies to establish 
a causal association between BV and PTX and elucidate the 
mechanisms underlying this effect.
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